Home Companies Catalysts Deep Dives
Clesrovimab MK-1654 FILED
Drug Profile
ModalityAntibody
RouteIM
Therapy AreaInfectious Disease
Peak Sales Est$2000M
Formulations[]
Companies
MRK (ORIGINATOR)100%
Mechanism: RSV F-protein neutralizing
Expert: Anti-RSV fusion protein monoclonal antibody
Everyday: Blocks RSV from entering cells
Targets: ["RSV F"]
Programs (1)
IndicationStageKey StudyRegional Status
RSV PreventionFILEDMK-1654-004[]
Notes
Long-acting RSV prevention in infants. Competing with Sanofi/AZN nirsevimab.
Data from Supabase · Updated 2026-03-24